Skip to Content
Merck
All Photos(1)

Key Documents

G1043

Sigma-Aldrich

Guanfacine hydrochloride

≥98% (HPLC)

Synonym(s):

N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C9H9Cl2N3O · HCl
CAS Number:
Molecular Weight:
282.55
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

color

white

solubility

H2O: soluble 12 mg/mL at 60 °C

originator

Promius

SMILES string

Cl.NC(=N)NC(=O)Cc1c(Cl)cccc1Cl

InChI

1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H

InChI key

DGFYECXYGUIODH-UHFFFAOYSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

Application

Guanfacine hydrochloride has been used as an α2A adrenoceptor agonist to test its protective effect on hypobaric hypoxia (HH) and in rat brain to measure blood oxygenation level dependent (BOLD) response.

Biochem/physiol Actions

Guanfacine stimulates the brain postsynaptic α2 adrenergic receptor (AR) and mediates the prefrontal cortical (PFC) neuronal regulation and strengthens their network. Guanfacine improves the density of neuronal dendrites and is useful in treating neuropsychiatric disorders. It modulates the synaptic and cytoskeletal proteins expression in prefrontal cortical (PFC) neurons and may improve hypobaric hypoxia (HH) induced PFC dysfunctions. Guanfacine enhances cognitive function and is recommended for attention deficit hyperactivity disorder (ADHD) therapy.
α-2 noradrenergic receptor agonist.

Features and Benefits

This compound was developed by Promius. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Timothy E Wilens et al.
Journal of the American Academy of Child and Adolescent Psychiatry, 51(1), 74-85 (2011-12-20)
To examine efficacy, tolerability, and safety of guanfacine extended release (GXR; ≤4 mg/d) adjunctive to a long-acting psychostimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years of age with suboptimal, but partial, response
Once-daily treatment of ADHD with guanfacine: patient implications
Strange BC
Neuropsychiatric Disease and Treatment, 4(3), 499-499 (2008)
Jean Lachaine et al.
Postgraduate medicine, 124(3), 139-148 (2012-06-14)
To understand attention-deficit/hyperactivity disorder (ADHD) treatment patterns and estimate adherence and persistence in Quebec, Canada. This cross-sectional, retrospective prescription claims analysis used a random sample of 15 838 patients with ADHD from a Quebec database (Régie de l'assurance maladie du
Yuanyuan Li et al.
Bioanalysis, 4(12), 1445-1456 (2012-07-17)
Direct analysis of dried blood spot (DBS) samples was investigated using a prototype semi-automated robotic device that allows the direct elution of sample spots from a DBS paper card to an online SPE cartridge. The eluted SPE samples were analyzed
Guanfacine promotes neuronal survival in medial prefrontal cortex under hypobaric hypoxia
Kauser H, et al.
Brain Research, 1636, 152-160 (2016)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service